Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
A HPLC-UV Method for the Quantification of Regorafenib in Tumor
View through CrossRef
Regorafenib has been approved for the treatment of colorectal cancer, gastrointestinal stromal tumor and hepatocellular carcinoma. High-performance liquid chromatography (HPLC) was developed and validated for determination of regorafenib in xenograft tumors. After protein precipitation with acetonitrile, regorafenib were separated using gradient elution (C18 Ultrabase column). Quantification was performed at 262 nm. Calibration curves were linear over the range 48.8-50000 ng/ml. The assay was applied to the determination of the drug in the tumor of nude mice receiving regorafenib 50 mg orally, and could be useful for therapeutic drug monitoring of regorafenib in routine clinical practice.
Neoplasia Research
Title: A HPLC-UV Method for the Quantification of Regorafenib in Tumor
Description:
Regorafenib has been approved for the treatment of colorectal cancer, gastrointestinal stromal tumor and hepatocellular carcinoma.
High-performance liquid chromatography (HPLC) was developed and validated for determination of regorafenib in xenograft tumors.
After protein precipitation with acetonitrile, regorafenib were separated using gradient elution (C18 Ultrabase column).
Quantification was performed at 262 nm.
Calibration curves were linear over the range 48.
8-50000 ng/ml.
The assay was applied to the determination of the drug in the tumor of nude mice receiving regorafenib 50 mg orally, and could be useful for therapeutic drug monitoring of regorafenib in routine clinical practice.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Recent Developments in Regorafenib Treatment for Gastrointestinal Cancers: Presentations at the Meeting of the European Society for Medical Oncology (ESMO) Congress 2016
Recent Developments in Regorafenib Treatment for Gastrointestinal Cancers: Presentations at the Meeting of the European Society for Medical Oncology (ESMO) Congress 2016
The European Society for Medical Oncology (ESMO) Congress was held in Copenhagen, Denmark from 7th–11th October 2016. The use of the promiscuous multikinase inhibitor regorafenib (...
Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer Treatment
Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer Treatment
Abstract
Objectives
Bone sarcomas are aggressive malignancies with limited treatment options in advanced stages. Regorafenib, a...
Abstract 1019: Investigation of cabozantinib, a MET and VEGFR2 inhibitor, on tumor metabolism and efficacy in a colorectal cancer patient-derived tumor explant model
Abstract 1019: Investigation of cabozantinib, a MET and VEGFR2 inhibitor, on tumor metabolism and efficacy in a colorectal cancer patient-derived tumor explant model
Abstract
Background:
Anti-angiogenic therapy is commonly used for the treatment of metastatic colorectal cancer (mCRC). Although patients derive some ...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Massive Proteinuria which Rapidly Resolved after Discontinuation of Regorafenib
Massive Proteinuria which Rapidly Resolved after Discontinuation of Regorafenib
Abstract: Regorafenib is treatment option of cancers. It is associated with several adverse effects, including proteinuria. We report a massive proteinuria associated with regorafe...
Regorafenib
Regorafenib
The process of angiogenesis is a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important proangiogenic facto...
Combine radiomics models and multi-omics data stratified patients with AFPhigh - HCC Sensitivity to regorafenib.
Combine radiomics models and multi-omics data stratified patients with AFPhigh - HCC Sensitivity to regorafenib.
Motivation: High expression of serum AFP (>400 ng/mL) in HCC patients predicts poor prognosis. Goal(s): Identify AFP-high HCC patients who are responsive to regorafenib. Approac...